


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

What is claimed is:

1. (currently amended) A compound of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof;



(1)

wherein

R<sup>1</sup> and R<sup>2</sup> are independently hydrogen, F, CF<sub>3</sub>, C<sub>1-3</sub>alkyl, or R<sup>1</sup> and R<sup>2</sup> may together with the carbon atom to which they are attached form a 3 to 6-membered cycloalkyl ring;

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub>alkyl, perfluoroC<sub>1-6</sub>alkyl, -OC<sub>1-3</sub>alkyl, perfluoroOC<sub>1-6</sub>alkyl, halogen, or cyano;

R<sup>7</sup> and R<sup>8</sup> are independently H, F, CF<sub>3</sub>, or C<sub>1-3</sub>alkyl, and the carbon to which R<sup>7</sup> and R<sup>8</sup> are bonded is attached to the benzene ring either meta or para to the depicted oxygen;

n is 1 or 2;

y is 1 or 2;

R<sup>6</sup> is phenyl or a 5- or 6-membered heteroaryl group, where the phenyl or heteroaryl group is optionally substituted with 1, 2, or 3 moieties selected from the group consisting of C<sub>1-6</sub>alkyl, halogen, perfluoroC<sub>1-3</sub>alkyl, OC<sub>1-3</sub>alkyl, perfluoroOC<sub>1-3</sub>alkyl, SC<sub>1-3</sub>alkyl, SO<sub>2</sub>C<sub>1-3</sub>alkyl, SO<sub>2</sub>C<sub>1-3</sub>perfluoroalkyl, SOC<sub>1-3</sub>perfluoroalkyl, SOC<sub>1-3</sub>alkyl, perfluoroSC<sub>1-3</sub>alkyl, CN, phenyl (optionally substituted with one or two groups selected from halogen, C<sub>1-3</sub>alkyl, OC<sub>1-3</sub>alkyl, acetyl, CN, and perfluoroC<sub>1-3</sub>alkyl), and 5- or 6-membered heteroaryl (optionally substituted with one group selected from C<sub>1-3</sub>alkyl, C<sub>3-6</sub>cycloalkyl, perfluoroC<sub>1-3</sub>alkyl, NHC<sub>1-3</sub>alkyl, and N(C<sub>1-3</sub>alkyl)<sub>2</sub>); and

R<sup>3</sup> is a 5- or 6-membered heteroaryl group optionally substituted by 1 or 2 moieties selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, perfluoroC<sub>1-</sub>

PU4675-USw

alkyl, OC<sub>1-3</sub>alkyl, phenyl (optionally substituted with one or two moieties selected from C<sub>1-3</sub>alkyl, halogen, OC<sub>1-3</sub>alkyl, acetyl, CN, perfluoroC<sub>1-3</sub>alkyl, and perfluoroC<sub>1-3</sub>alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from C<sub>1-3</sub>alkyl, halogen, OC<sub>1-3</sub>alkyl, acetyl, CN, and perfluoroC<sub>1-3</sub>alkyl), hydroxyC<sub>1-3</sub>alkyl, C<sub>3-7</sub>cycloalkyl, cyanoC<sub>1-3</sub>alkyl, acetyl, nitro, N(CH<sub>3</sub>)<sub>2</sub>, NHR<sup>21</sup> (where R<sup>21</sup> is C<sub>1-3</sub>alkyl, -C(O)C<sub>1-3</sub>alkyl, -C(O)OC<sub>1-3</sub>alkyl, or SO<sub>2</sub>CH<sub>3</sub>), piperidin-4-yl (substituted at nitrogen with a moiety selected from C<sub>1-3</sub>alkyl, benzyl, acetyl, C(O)OC<sub>1-3</sub>alkyl, C(O)Obenzyl, C(O)NH<sub>2</sub>, C(O)NHC<sub>1-3</sub>alkyl, SO<sub>2</sub>CH<sub>3</sub>), 4-(4-fluorophenyl)piperazin-1-ylmethyl, morpholin-4-ylmethyl, tetrahydrofuran-3-yl, or two adjacent carbon atoms in the heteroaryl could be substituted to form a benzene ring thus forming a fused bicycle and wherein the resulting benzene ring is optionally substituted with one or two moieties selected from C<sub>1-3</sub>alkyl, halogen, and perfluoroC<sub>1-3</sub>alkyl.

2. (original) A compound of Claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently hydrogen or C<sub>1-3</sub>alkyl.
3. (previously presented) A compound according to Claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are both hydrogen or both methyl.
4. (previously presented) A compound according to Claim 2 wherein R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-3</sub>alkyl, perfluoroC<sub>1-3</sub>alkyl, -OC<sub>1-3</sub>alkyl, perfluoroOC<sub>1-3</sub>alkyl, halogen, or cyano.
5. (previously presented) A compound according to Claim 4 wherein at least one of R<sup>4</sup> and R<sup>5</sup> are hydrogen
6. (previously presented) A compound according to Claim 5 wherein one of R<sup>4</sup> and R<sup>5</sup> is hydrogen and the other is not.
7. (original) A compound according to Claim 6 wherein the one of R<sup>4</sup> and R<sup>5</sup> that is not hydrogen is ortho to the depicted oxygen.
8. (previously presented) A compound according to Claim 5 wherein R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or methyl.

PU4675-USw

9. (previously presented) A compound according to Claim 5 wherein  $R^7$  and  $R^8$  are both hydrogen or both methyl.

10. (previously presented) A compound according to Claim 9 wherein  $y$  is 1.

11. (previously presented) A compound according to Claim 10 wherein  $R^8$  is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl,  $CF_3$ ,  $OCF_3$ , 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from  $C_{1-3}$ alkyl,  $C_{3-8}$ cycloalkyl, perfluoro $C_{1-3}$ alkyl,  $NHC_{1-3}$ alkyl, and  $N(C_{1-3}alkyl)_2$ ).

12. (previously presented) A compound according to any Claim 11 wherein  $R^3$  is selected from the group consisting of pyrimidine, pyridine, pyridazine, pyrazine, 1,2,4-oxadiazole, oxazole, and thiazole; and is optionally substituted by a moiety selected from the group consisting of halogen,  $C_{1-6}$ alkyl, perfluoro $C_{1-6}$ alkyl, phenyl (optionally substituted with one or two moieties selected from  $C_{1-3}$ alkyl, halogen,  $OC_{1-3}$ alkyl, acetyl, CN, and perfluoro $C_{1-3}$ alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from  $C_{1-3}$ alkyl, halogen,  $OC_{1-3}$ alkyl, acetyl, CN, and perfluoro $C_{1-3}$ alkyl), hydroxy $C_{1-3}$ alkyl, and  $C_{3-7}$ cycloalkyl, or  $R^3$  may be substituted to form a fused bicycle selected from benzoxazole and benzothiazole.

13. (previously presented) A compound according to Claim 12 wherein  $R^3$  is a pyrimidine or a pyridine; and is optionally substituted by a moiety selected from the group consisting of halogen,  $C_{1-6}$ alkyl, perfluoro $C_{1-6}$ alkyl, phenyl (optionally substituted with one or two moieties selected from  $C_{1-3}$ alkyl, halogen,  $OC_{1-3}$ alkyl, acetyl, CN, and perfluoro $C_{1-3}$ alkyl), 5- or 6-membered heteroaryl, hydroxy $C_{1-3}$ alkyl, and  $C_{3-7}$ cycloalkyl.

14. (original) A compound according to Claim 1 selected from the group consisting of:

2-(4-{2-[[2,4-Bis(trifluoromethyl)benzyl](5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)-2-methoxyphenoxy]-2-methylpropanoic acid;

2-[2-Cyano-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[3-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-fluoro-2-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-(2-((4-chlorobenzyl)(5-ethylpyrimidin-2-yl)amino)ethyl)phenoxy)-2-methylpropanoic acid;

2-[4-(2-((5-ethylpyrimidin-2-yl)[3-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)(4-fluorobenzyl)amino)ethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]acetic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]acetic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-propylphenoxy]acetic acid;

5-Ethyl-N-[2-[3-propyl-4-(2H-tetraazol-5-ylmethoxy)phenyl]ethyl]-N-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]acetic acid;

5-ethyl-N-[2-methyl-2-[4-(2H-tetraazol-5-ylmethoxy)phenyl]propyl]-N-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]acetic acid;

PU4675-USw

2-[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)-2-propylphenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)-2-propylphenoxy]acetic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-methylphenoxy]-2-methylpropanoic acid;

2-[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-(trifluoromethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-methylphenoxy]acetic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)-2-fluorophenoxy]acetic acid;

[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]acetic acid;

2-[4-(2-((5-Ethylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Isopropylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-Methyl-2-[4-(2-((5-(2,2,2-trifluoroethyl)pyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]propanoic acid;

2-[4-(2-((5-(Hydroxymethyl)pyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(3-((5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)propyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-([4-(2-Chlorophenyl)-1,3-thiazol-2-yl])[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-([4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl])[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

15. (original) A compound according to Claim 1 selected from the group consisting of: 2-[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-([4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-([4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid, and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

16. (original) A compound according to Claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are both hydrogen or both methyl; at least one of R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>7</sup> and R<sup>8</sup> are both hydrogen or both methyl; y is 1; R<sup>6</sup> is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF<sub>3</sub>, OCF<sub>3</sub>, 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from C<sub>1-3</sub>alkyl, C<sub>3-6</sub>cycloalkyl, perfluoroC<sub>1-3</sub>alkyl, NHC<sub>1-3</sub>alkyl, and N(C<sub>1-3</sub>alkyl)<sub>2</sub>); and R<sup>3</sup> is a thiazole, a pyrimidine, or a pyridine and is optionally substituted by a moiety selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, perfluoroC<sub>1-6</sub>alkyl, phenyl (optionally substituted with one or two moieties selected from C<sub>1-3</sub>alkyl, halogen, OC<sub>1-3</sub>alkyl, acetyl, CN, and perfluoroC<sub>1-3</sub>alkyl), 5- or 6-membered heteroaryl, hydroxyC<sub>1-3</sub>alkyl, and C<sub>3-7</sub>cycloalkyl.

17. (previously presented) A compound according to Claim 1 wherein the compound is a hPPAR agonist.

Claims 18-20 are deleted.

21. (previously presented) A pharmaceutical composition comprising a compound according to Claim 1.

Claims 22 and 23 are deleted.